Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_assertion type Assertion NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_head.
- NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_assertion description "[KRAS mutation rates increased significantly from primary tumors to lymph node metastases and distant metastases within the neuroendocrine negative CRC group (44%, 53%, 64%, respectively, P = 0.042).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_provenance.
- NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_assertion evidence source_evidence_literature NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_provenance.
- NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_assertion SIO_000772 25337237 NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_provenance.
- NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_assertion wasDerivedFrom befree-2016 NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_provenance.
- NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_assertion wasGeneratedBy ECO_0000203 NP1231549.RA6rL1RjubtlRgfXn71dWjkF022ALNFfs3_0WwKjFMEkA130_provenance.